ManuBright Care 2 is a critical illness insurance product provided and underwritten by Manulife (International) Limited (Incorporated in Bermuda with limited liability) (‘Manulife’). The above provides only general information on this product. It does not form part of the policy and does not contain full terms of the policy. You should read the policy provisions for the exact terms and conditions that apply to this product. You can ask us for a copy.

1. The juvenile disease CI benefit is available if the policy is issued before the life insured reaches the age of 16 and the life insured is diagnosed with a juvenile disease before the age of 18.
2. The ICU benefit, continuous care benefits and disability care booster are subject to terms and conditions, please see the product leaflet and policy provisions for details.
   
3. We guarantee that the basic plan premiums for the initial basic plan notional amount remain unchanged throughout the premium payment period. However, we do not guarantee that the premium and guaranteed cash value due to an increase in the basic plan notional amount, including those increases triggered by using the inflation protector option.

^*The statement we have made about this feature being ‘first in market’ is based on comparing it with other publicly available critical illness plans issued by Hong Kong’s major life insurance companies for individual customers as at 27 July, 2020.

Diagnosis or treatment performed in mainland China:

For major critical illness, early stage critical illness, juvenile disease and Such Disablement diagnosed in mainland China, we will only recognize the diagnosis made by a specialist medical practitioner of a hospital on the list of designated hospitals in mainland China we publish. For Qualified ICU Stay in mainland China, we will only recognize the hospital which is included on the list of designated hospitals in mainland China we publish. We may revise the list of designated hospitals in mainland China from time to time without giving prior notice.